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Summary Four human cell lines derived from malignant gliomas were immunohistochemically examined for
their content of estramustine-binding protein (EMBP). EMBP was detected in a large amount in all glioma
cells during the entire cell cycle. EMBP has previously been demonstrated to be the major receptor protein in
prostatic cancers for the cytostatic drug estramustine-phosphate (EMP). EMP caused a dose-dependent
inhibition of exponentially growing cells by increasing the number of cells in G2/M stage of the cell cycle as
monitored by flow cytofluorometry. The effect may be coupled to arrest of the glioma cells at metaphase. The
presence of EMBP may suggest a selective binding and effect of EMP in glioma cells.
Estramustine phosphate (EMP), a cytotoxic nornitrogen-
mustard derivate of estradiol-17,B-phosphate, is generally
accepted in the treatment of advanced prostatic carcinoma
(Madajewics et al., 1980). Estramustine phosphate is
dephosphorylated in the gastrointestinal tract to estramus-
tine, which to a high extent is oxidized to estromustine
(Andersson et al., 1981). The exact mechanism of action by
EMP on malignant tissue is incompletely understood. EMP
has been shown to induce mitotic arrest in human prostatic
cancer cell lines by interaction with the mitotic spindle
(Hartley-Asp, 1984). Recently EMP was found to generate
free oxygen-radicals (Grankvist et al., 1988).
The presence of a specific binding protein, estramustine
binding protein (EMBP), could be important for the effect.
EMBP has been demonstrated in prostatic cancer tissue
cytosol from rat and man (Bjork et al., 1982). EMBP, which
is distinct from the estrogen receptor, binds estramustine and
the main metabolite estromustine with high affinity, and thus
may be important for drug action in malignant target tissue
(Forsgren et al., 1979b; Bjork et al., 1985).
In this report we demonstrate the presence of EMBP in
cultured human malignant glioma cell lines by an immuno-
histochemical method using mouse monoclonal antibodies
with cross-reactivity to the human counterpart (Bergh et al.,
submitted; Nilsson et al., submitted). Furthermore, the
effects of EMP on cellular growth were examined.
Materials and methods
Cell culture
Four human glioma cell lines (U-251 MG, U-118 MG, U-
105 MG, U-87 MG) were used (Westermark et al., 1973).
The cells were grown as monolayer cultures in Eagles MEM
supplemented with 10% foetal calf serum, penicillin, strepto-
mycin and fungizone. They were incubated at 37°C in
humidified atmosphere containing 5% CO2. Synchronization
was achieved by seeding the cells in microtitre wells (Becton
& Dickinson labware, Oxnard, CA) in 0.1 mg of Eagle's
medium at a concentration of 104cells/well. The next day the
medium was changed to MEM without serum and incubated
for 4-6 additional days. The synchrony (>85% cells in Go/
Gl) was controlled by flow cytofluorometry.
Micronised estramustine phosphate
(Estracyt'(C, AB LEO, Helsingborg, Sweden), 300mg, was
dissolved in 8ml sterile water and diluted in Eagles medium
to appropriate concentrations (range of l-40jgml-1), and
included in the incubation media (see above).
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Cell proliferation
Cell proliferation was measured by seeding cells (U-251 MG,
U-118MG, U-105MG) in 24-well tissue culture dishes (Cos-
tar, Cambridge, MA USA) at 6 x 104 -1.2 x 105 cells/well
depending on cell line. Medium was changed three times a
week. Cells were harvested by incubation with 0.2ml EDTA
(0.5mM) for 5min followed by trypsin (0.1%). A Linson 431
counter (Linson Instruments, Stockholm, Sweden) was used
to analyze cell number. Reversibility experiments were per-
formed on all cell lines. On the third day of culture, after
repeated washing a group of cells were reincubated with
fresh medium devoid of estramustine phosphate.
Flow cytofluorometry
Cells were stained with propidiumiodide according to Vinde-
lov (1977) and analyzed in a Model 4800A flow cytofluoro-
meter (Bio/Physics Systems Inc., Mahopac, NY, USA). The
DNA curves were obtained in a TN 1705 pulse height
analyzer (Tracor Northern Inc., Middleton, WI, USA).
Immunohistochemical demonstration of EMBP
Malignant glioma cells from stock cultures (see above) were
washed in PBS three times and spun down at 500g for
10min. The pellets were snap frozen at -70°C, followed by
freeze sectioning at time of use. The cells were then analyzed
for the presence of EMBP using the conventional indirect
antibody-peroxidase technique. The techniques have been
described in detail elsewhere (Sternberger, 1979; Bergh et al.,
1985a).
Endogenous peroxidase activity was blocked by addition
of H202 in methanol. The primary mouse monoclonal
antibody (Mab EMBP 1) raised against purified rat EMBP,
with demonstrated cross-reactivity to human EMBP (Bergh
et al., 1988), was added diluted 1/10 to the sections for 1-1 h.
After sequential washings in PBS the rabbit anti mouse
avidin-biotin peroxidase antiperoxidase complexes (Vectas-
tain, Burlingame, California, USA) were added. The staining
reaction was developed in DMSO/ethylcarbozole, followed by
counterstaining with haemathoxylin and mounting in
glycerol-gelatin. Two small cell lung cancer cell lines U-1285
and U-1906 (Bergh et al., 1985b) were used as negative and
positive controls respectively. U-1285 has previously been
demonstrated to contain only minute amounts of EMBP
using fast-protein liquid chromatography, whereas U-1906
has been shown to exhibit large amounts (Bergh et al.,
submitted). Furthermore, for each tested cell line - another
negative control was obtained by omitting the primary
monoclonal antibody. Immunohistochemical staining results
were semiquantitatively analyzed according to the scheme in
Table I.
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Table I
Histopathological Monoclonal EMBP-antibodya
Cell line diagnosis Intensity in staining - proportion of positive cellsb
87-MG Astrocytoma grade IV' + + + >90%
Negative control - 0%
105-MG Astrocytoma grade IV' + + + >90%
Negative control 0%
118-MG Astrocytoma grade IV' + + + >90%
Negative control - 0%
251-MG Astrocytoma grade IV' + + + >90%
Negative control - 0%
U-1285 Small cell carcinoma2 - <1% (rare positive cells)
Negative control - 0%
U-1906 Small cell carcinoma2 + + + >90%
Negative control - 0%
'Westermark et al., 1973; 2Bergh et al., 1984; aStaining intensity in a four graded scale: Negative, +, + +, +++;
'Number of positive cells in five groups: <1%, 1-10%, 1-50%, 51-90%, >90%.
a
Immunohistochemical demonstration of EMBP
All studied malignant glioma cell lines contained high
amounts of EMBP as monitored with the monoclonal anti-
body (Table I). The intensity in positive staining, localized to
the cytoplasm and the proportion of positive cells (>90%)
were similar in all investigated cell lines. The staining pattern
was similar to that previously found in the positive control,
the human small cell lung cancer cell line U-1906 (Bergh et
al., submitted). The same intense positive staining was
observed in all phases of the cell cycle investigated (Go/
Gl, S, G2/M).
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Antiproliferative effects
Cells were grown with different estramustine phosphate
(EMP) concentrations (Figures 1 and 2). EMP caused a
dose-dependent inhibition of growth of all three cell lines
tested in the concentration range 1-40pgml-'. All cell lines
were maximally inhibited by 20pgml-1EMP during 6 days
incubation. There was a small difference in the sensitivity of
the different cell lines with U- 18-MG being the most
sensitive. In all investigated cell lines the inhibitory effect of
EMP was reversed by washing and reincubation in fresh
medium. Figure 3 illustrates the reversal of the inhibitory
effect even in a rather high concentration of 20 ,gml 1EMP
on U-105 MG cells.
Effect on cell cycle
To examine whether a block existed in a certain cell cycle
phase, cell cycle parameters were studied by cytofluorometry.
Estramustine phosphate treatment for 3 days caused a large
increase in the number of cells in G2/M compared to
controls (Figure 4, Table II). Consequently this diminished
the proportion ofGO/GI cells. Estramustine did not seem to
block cells in a resting Go stage. All cells also had the
morphological characteristics of mitotic cells (Figure 2b).
Discussion
EMBP has been described as a major androgen dependent
secretory protein in the rat ventral prostate (Pousette et al.,
1981). It is distinct from the estrogen receptor, has a low
affinity for estrogens but binds estramustine with a dissocia-
tion constant (Kd) of 2 x 10 - 8 M (Forsgren et al., 1979b,
Bjork et al., 1985). A human analogue to this protein has
been demonstrated in normal benign hyperplastic and
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Figure I Antiproliferative effects of different concentrations of
estramustine on three human glioma cell lines; (a) U-1OSMG, (b)
U-118MG, (c) U-251 MG. O=control, * =5pg/ml-1,
A=/10jg/ml-1, *=20pg/ml-1.
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Figure 4 Cell cycle histograms after estramustine treatment
(20 ug/ml-1) for 24 hours analyzed cytofluorigraphically.
Table II Cell cycle distribution after estramustine treat-
ment (20-40,ug/ml-1) of different glioma cell lines for 24
hours. In each experiment at least 20 x 103 cells were
analyzed by flow cytofluorometry
GO/G,S G2/M
(%o) (0) (%o)
251 MG Control 73 8 19
EMP (40pg/ml-1) 29 19 52
105 MG Control 71 11 18
EMP (20 ig/ml 1) 10 23 67
118 MG Control 75 7 18
EMP (20pg/ml-1) 23 9 68
Figure 2 Untreated control cells (a) and estramustine treated
cells (b). Note the typical appearance of cells in mitosis (G2/M)
following estramustine. Inverse microscope photography.
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Figure 3 Proliferation of U-105 MG cells in the presence of
20pg/ml of estramustine phosphate and after washing and re-
incubation with normal medium on the third day of culture.
O =control, * = EMP 20 jg/ml-1, 2 = after washing and
reincubation.
malignant prostatic tissue (Bjork et al., 1982) and suggested
to act as an accumulator of estramustine and estromustine
during clinical therapy (Bjork et al., 1985). EMBP was
originally identified when looking for the mechanism of action
by estramustine phosphate (EMP), a drug which is accepted
in the treatment of advanced prostatic carcinoma. In the
present study we demonstrate for the first time the presence
of EMBP in human glioma cell lines and that EMP has the
capacity of inhibiting the growth of glioma cells in vitro.
The mouse monoclonal antibody (Mab EMBP-1) used
here, raised against purified rat EMBP displays a significant
reactivity with human tissues previously demonstrated to be
positive with the polyclonal rabbit antiserum to EMBP
(Forsgren et al., 1979a, Bjork et al., 1982). Significant
interspecies immunoreactivities have also been demonstrated
together with specific staining with the Mab EMBP-1 in
normal human prostatic epithelium and prostatic carcinomas
(Nilsson et al., 1988, Bergh et al., 1988).
Previously EMBP has been detected in the pituitary gland
and cerebral cortex of male and female rats (Forsgren et al.,
1979a). While the biological role of this glycoprotein within
the CNS remains to be elucidated its presence of EMBP in
glioma cells may have a clinical interest in the management
of malignant gliomas. As previously demonstrated in the rat
(Bjork et al., 1982) immunohistochemical detection of EMBP
was only accomplished in the cytoplasm of the glioma cells.
To what extent the binding protein is involved in the
cytotoxic action of estramustine on glioma cells as demon-
strated here is unclear.
The cytotoxic effect of EMP is believed to be mediated by
a direct action of the main metabolites estramustine and
estromustine (Bjork et al., 1985). Mitotic arrest and inhibi-
tion of DNA synthesis were more pronounced by the
estramustine complex than for the nor-nitrogen mustard
alone (Hartley-Asp et al., 1982; Hartley-Asp, 1984; Bjork et
al., 1985). In our in vitro system it is difficult to state which
of the components is responsible for the growth-inhibition of
glioma cells.
In the present cell cultures the effect was clearly dose-
dependent and maximal inhibition was achieved at concent-
rations from 10-20 ugml-. Using these concentrations
exponentially growing glioma cells were accumulated in the
G2/M stage and the fraction of G1/GO, was reduced. These
data are in good agreement with previous studies on various
prostatic cancer cell lines (Hartley-Asp et al., 1982) and cell
lines of small cell lung cancer (Westlin et al., unpublished
results). Moreover, the effects of EMP seemed to be rever-
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cells do not regrow. This would be the effect if the used cells
were not from a pure clonal cell line. The exact mechanism
for this interaction between EMP and tumour cells is
unknown but has recently been suggested to involve free
oxygen radicals (Grankvist et al., 1988).
In conclusion, a protein with immunohistochemical char-
acteristics related to EMBP has been demonstrated for the
first time in human malignant glioma cells. The physiological
significance of this observation remains to be elucidated.
EMBP has been proposed to participate in the mechanism
for a specific binding of the metabolites of EMP (Bjork et
al., 1985). Detection of EMBP in tumour cells could possibly
be of future value for the selection of patients that may
benefit from EMP treatment. Further studies on the mecha-
nism of action of EMP and it's specific binding protein
within the CNS are certainly justified.
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